X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with Strides Arcolab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs STRIDES SHASUN LTD - Comparison Results

STRIDES SHASUN LTD 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA STRIDES SHASUN LTD SHASUN PHARMA/
STRIDES SHASUN LTD
 
P/E (TTM) x 123.9 41.1 301.1% View Chart
P/BV x 8.5 1.0 834.6% View Chart
Dividend Yield % 0.2 1.0 24.1%  

Financials

 SHASUN PHARMA   STRIDES SHASUN LTD
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
STRIDES SHASUN LTD
Mar-17
SHASUN PHARMA/
STRIDES SHASUN LTD
5-Yr Chart
Click to enlarge
High Rs941,275 7.4%   
Low Rs46918 5.0%   
Sales per share (Unadj.) Rs214.2389.6 55.0%  
Earnings per share (Unadj.) Rs5.328.0 19.1%  
Cash flow per share (Unadj.) Rs15.848.9 32.4%  
Dividends per share (Unadj.) Rs1.004.50 22.2%  
Dividend yield (eoy) %1.40.4 348.5%  
Book value per share (Unadj.) Rs53.3303.1 17.6%  
Shares outstanding (eoy) m56.6289.42 63.3%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.32.8 11.6%   
Avg P/E ratio x13.139.2 33.4%  
P/CF ratio (eoy) x4.422.4 19.7%  
Price / Book Value ratio x1.33.6 36.2%  
Dividend payout %18.716.1 116.5%   
Avg Mkt Cap Rs m3,95898,036 4.0%   
No. of employees `000NA5.8 0.0%   
Total wages/salary Rs m2,1645,881 36.8%   
Avg. sales/employee Rs ThNM6,005.9-  
Avg. wages/employee Rs ThNM1,014.0-  
Avg. net profit/employee Rs ThNM431.2-  
INCOME DATA
Net Sales Rs m12,12734,834 34.8%  
Other income Rs m2291,686 13.6%   
Total revenues Rs m12,35636,520 33.8%   
Gross profit Rs m1,0096,428 15.7%  
Depreciation Rs m5941,872 31.7%   
Interest Rs m4152,269 18.3%   
Profit before tax Rs m2303,973 5.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m04 -8.3%   
Extraordinary Inc (Exp) Rs m0-1,006 0.0%   
Tax Rs m-73470 -15.5%   
Profit after tax Rs m3022,501 12.1%  
Gross profit margin %8.318.5 45.1%  
Effective tax rate %-31.711.8 -267.6%   
Net profit margin %2.57.2 34.7%  
BALANCE SHEET DATA
Current assets Rs m6,88438,165 18.0%   
Current liabilities Rs m8,45630,402 27.8%   
Net working cap to sales %-13.022.3 -58.2%  
Current ratio x0.81.3 64.9%  
Inventory Days Days6277 79.7%  
Debtors Days Days108104 102.9%  
Net fixed assets Rs m4,97037,639 13.2%   
Share capital Rs m113894 12.7%   
"Free" reserves Rs m2,87526,210 11.0%   
Net worth Rs m3,02027,105 11.1%   
Long term debt Rs m1,81716,377 11.1%   
Total assets Rs m13,34781,168 16.4%  
Interest coverage x1.62.8 56.5%   
Debt to equity ratio x0.60.6 99.6%  
Sales to assets ratio x0.90.4 211.7%   
Return on assets %5.45.9 91.4%  
Return on equity %10.09.2 108.4%  
Return on capital %13.312.1 110.5%  
Exports to sales %46.40-   
Imports to sales %14.20-   
Exports (fob) Rs m5,622NA-   
Imports (cif) Rs m1,728NA-   
Fx inflow Rs m5,84313,465 43.4%   
Fx outflow Rs m2,1734,076 53.3%   
Net fx Rs m3,6699,389 39.1%   
CASH FLOW
From Operations Rs m3982,881 13.8%  
From Investments Rs m-1,635-7,051 23.2%  
From Financial Activity Rs m1,3093,382 38.7%  
Net Cashflow Rs m71-788 -9.0%  

Share Holding

Indian Promoters % 39.2 27.7 141.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.6 37.8 9.5%  
FIIs % 17.6 8.6 204.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 25.9 152.9%  
Shareholders   20,750 56,241 36.9%  
Pledged promoter(s) holding % 12.3 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   WOCKHARDT LTD.  J.B.CHEMICALS  MERCK LTD  BIOCON LTD  FULFORD INDIA  

Compare SHASUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Positively, Aavas Financiers IPO, and Top Stocks in Action Today(Pre-Open)

Share markets in India ended on a positive note yesterday with gains largely seen in the banking sector and healthcare sector.

Related Views on News

STRIDES SHASUN LTD Announces Quarterly Results (1QFY19); Net Profit Down 57.5% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, STRIDES SHASUN LTD has posted a net profit of Rs 38 m (down 57.5% YoY). Sales on the other hand came in at Rs 7 bn (down 21.2% YoY). Read on for a complete analysis of STRIDES SHASUN LTD's quarterly results.

STRIDES SHASUN LTD Announces Quarterly Results (4QFY18); Net Profit Down 99.2% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, STRIDES SHASUN LTD has posted a net profit of Rs 8 m (down 99.2% YoY). Sales on the other hand came in at Rs 7 bn (down 25.2% YoY). Read on for a complete analysis of STRIDES SHASUN LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Oh Yes! This is the Best Trading Opportunity in Two Decades(Profit Hunter)

Sep 21, 2018

Getting ready to buy stocks once this correction is over? This private sector bank should be on a profit hunter's radar.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

How To Identify Sachin Tendulkars And Rahul Dravids Of Tomorrow For Your Mutual Fund Portfolio(Outside View)

Sep 19, 2018

PersonalFN explains how to pick 'undiscovered' or lesser-known mutual funds that are capable of generating big gains for you.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA - NATCO PHARMA COMPARISON

COMPARE SHASUN PHARMA WITH

MARKET STATS